Buy Rating Affirmed for Viking Therapeutics on Promising VK0214 Trial Results and Strategic Focus on Obesity Program
Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report), retaining the price target of ...
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.45, representing a -0.3% change from its previous close.
Buy Rating Affirmed for Viking Therapeutics on Promising VK0214 and VK2735 Clinical Data
Viking Therapeutics (VKTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Viking Therapeutics reports positive data from trial of treatment for rare metabolic disorder X-ALD
Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often ...
Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams
On Wednesday, Viking Therapeutics Inc. (NASDAQ:VKTX) released data from the Phase 1b trial of VK0214, a novel small molecule ...
Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALD
Viking Therapeutics Inc.'s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...
BioSpace2d
Lilly’s Sprawling Obesity Clinical Program Underscores Challenges for Biotechs
Eli Lilly’s CEO David Ricks is confident his company and peer Novo Nordisk are years ahead in the weight loss space, as ...
marketinference2d
Did Analysts Get It Wrong About Viking Therapeutics (VKTX)?
It's been a strong day for Viking Therapeutics. Its shares are now trading at $67.11, marking a 6.5% change since the previous market close. An analyst favorite, the Pharmaceutical company has a ...
bovnews2d
Viking Therapeutics Inc (VKTX) Stock: Unveiling Its Hidden Strengths
On Monday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $63.01 which represents a decrease of $-1.95 or -3.00% from the prior close of $64.96. The stock opened at $65.61 and ...
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
In phase 2, VK2735 reduced patients' weight by about 15% after 13 weeks of treatment and maintained a clean safety profile.
bovnews6d
What’s Causing Viking Therapeutics Inc (VKTX) Stock’s -12.99% Drop Over the Last Six Months?
Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $64.11 which represents a decrease of $-0.58 or -0.90% from the prior close of $64.69. The stock opened at $64.6 and touched a low ...